The DuraHeart II which will be marketed by the HUGE Japanese company will open Asia for THOR. USA and EU clinical trials start in 2016.
With the HeartMate III and PHP in 2014, THOR's product pipeline and growth into a HUGE entity in the Accelerating HF field is assured
Tokyo – Terumo Corporation (TSE: 4543 Section 1) announced that it has entered a strategic alliance as of June 30, 2013 with Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, in the development of the smallest full capacity, next generation implantable left ventricular assist system using a unique centrifugal blood pump, DuraHeart® II (hereafter “DH-II”).
The alliance includes the sale of certain assets and licensing of intellectual properties related to DH-II. Thoratec will continue the development of DH-II, manage the clinical trial process in the U.S. and Europe, manufacture and plan commercial distribution in the Americas and Europe. Furthermore, Terumo becomes Thoratec’s exclusive distributor of DH-II in Japan and potentially other parts of Asia.
Thoratec anticipates a first-in-human implant of the DuraHeart-II pump in 2016 to be followed by clinical trials in the USA and other territories. Following clinical trials, the distribution partnership between Thoratec and Terumo should optimise patient access to the DuraHeart-II technology on a worldwide basis.“DuraHeart II brings a differentiated approach to mechanical circulatory support to Thoratec’s R&D portfolio and will be an integral component of our product development strategy, along with continued evolution of the HeartMate II system, next-generation pump platforms including HeartMate III and HeartMate PHP, which are expected to begin pivotal CE mark trials in the second half of 2013, and breakthrough cross-platform technologies such as our fully implantable system.”